Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 6 trials

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

4Total
Not Applicable (1)
Early P 1 (1)
P 2 (1)
P 3 (1)

Trial Status

Recruiting5
Unknown1

Clinical Trials (6)

Showing 6 of 6 trials
NCT06382948Phase 3Recruiting

Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.

NCT07222215Phase 2Recruiting

PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)

NCT04174352Early Phase 1Recruiting

FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer

NCT06548919RecruitingPrimary

Current Status of Treatment for Chinese Patients With ESR1-mutated HR+/HER2-advanced Breast Cancer

NCT06544577RecruitingPrimary

Safety of Elacestrant in ER+/HER2- and ESR1 Mutations MBC

NCT05814224Not ApplicableUnknown

Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA

Showing all 6 trials

Research Network

Activity Timeline